Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryCommunity Health Plan Washington genetic eye testi…
    Ask Trek AI about this page
    ModifiedCommunity Health Plan WashingtonPolicy N/A

    Concert Genetic Testing: Eye Disorders V1.2025

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, investigational status, and criteria for genetic testing for macular degeneration, inherited retinal dystrophies, and other genetically-associated eye disorders for members of the payer network.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyConcert Genetic Testing: Eye Disorders V1.2025
    Policy CodePolicy N/A
    Change TypeCriteria updates and code removals (material)
    Effective DateN/A
    Last ReviewNov 24, 2024
    Next Review DateN/A
    Key ActionVerify current covered test codes and obtain prior authorization when required before ordering genetic tests for inherited retinal dystrophies.
    SourceLink
    POLICY UPDATE CHANGES

    Macular Degeneration: Removed CPT code 81406 from Fulgent Genetics test in Policy Reference Table and within criteria.

    Clinical criteria for Inherited Retinal Dystrophies Multigene Panel Analysis were updated and the criteria set name changed (formerly 'RPE65 Sequencing and/or Deletion/Duplication Analysis').

    Other Covered Eye Disorders: Removed 'Retinitis Pigmentosa' from disorders list (covered under Inherited Retinal Dystrophies criteria).

    A glaucoma-related criteria set was retired due to low order and claim volume.

    Inherited Retinal Dystrophies Multigene Panel Analysis: updated access date for online reference.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~500genes identified related to inherited eye diseases
    1/3proportion of human diseases that may affect the eyes
    81404–81479CPTs for inherited retinal panel
    81404,etcCPTs investigational for AMD
    V1.2025policy version

    Coverage Criteria

    Inherited retinal dystrophies — medically necessary

    Covered when ALL of the following are met

    Inherited Retinal Dystrophies criteria: A. Member has findings consistent with ONE of: (1) rod-cone degeneration (e.g., retinitis pigmentosa), OR (2) cone-rod degeneration (e.g., achromatopsia), OR (3) chorioretinal degeneration, OR (4) macular dystrophy; AND B. The test includes, at a minimum, the RPE65 gene.

    Panel CPTs: 81404, 81406, 81408, 81434, 81479

    Macular degeneration — investigational

    Macular degeneration: Genetic testing for macular degeneration (CPT 81404, 81408, 81479, 81599, 0205U) is considered investigational.

    Other covered eye disorders — medically necessary when clinically indicated

    Covered when ALL of the following are met

    Other covered eye disorders: Genetic testing to establish or confirm diagnosis of listed rare eye disorders is considered medically necessary when the member demonstrates clinical features consistent with the disorder; list includes Duane syndrome, familial exudative vitreoretinopathy, aniridia, X-linked congenital retinoschisis, presenile cataracts.

    Other eye disorders not listed are evaluated using the General Approach to Genetic and Molecular Testing policy.

    Updated and retired criteria sets

    Policy updates affecting coverage criteria include:

    Inherited Retinal Dystrophies Multigene Panel Analysis: Criteria set renamed from 'RPE65 Sequencing and/or Deletion/Duplication Analysis' and clinical criteria updated to be more consistent with guidelines.

    Covered when criteria in renamed panel are met per policy; details of specific genetic/phenotypic criteria are in other sections not included in this excerpt.

    Glaucoma criteria: A previously existing glaucoma criteria set was retired due to rarity of testing (low order volume and low claim volume).

    Retired criteria no longer apply.

    Macular Degeneration testing: CPT code 81406 was removed from a listed Fulgent Genetics test and the policy reference table was updated.

    Providers should reference updated policy reference tables for current acceptable codes and tests.

    Other list edits:

    Genetic testing for macular degeneration is classified as investigational and is excluded from medical necessity coverage. The policy specifically lists CPT codes 81404, 81408, 81479, 81599, and 0205U as investigational for macular degeneration testing and notes that such testing may be denied on that basis.

    The policy removes Retinitis Pigmentosa from the 'Other Covered Eye Disorders' list because it is now addressed under the Inherited Retinal Dystrophies Multigene Panel Analysis criteria set (formerly titled RPE65 sequencing/deletion-duplication analysis). Providers should therefore follow the inherited retinal dystrophy criteria when requesting genetic testing for retinitis pigmentosa.

    Routine genetic testing for genetically complex, multifactorial disorders such as age-related macular degeneration (AMD) is not supported by current evidence and is considered investigational. Guideline statements cited in the policy note that routine AMD genotyping does not presently change management (including use of AREDS supplements or anti-VEGF treatment decisions) and that testing should be limited to CLIA-certified laboratories with appropriate expertise if performed.

    The excerpt does not list a separate, explicit 'not medically necessary' statement for every test; however, the policy documents material changes and retirements that affect coverage. Tests and codes removed from the policy reference table (for example, removal of CPT 81406 from a previously listed Fulgent Genetics macular degeneration test) and retired criteria sets may result in those tests no longer being covered or requiring updated coding and prior authorization.

    Coding and Test References

    Macular degeneration / example CPTsCPT
    81479Unlisted molecular pathology procedure
    81599Unlisted clinical laboratory test
    0205UProprietary laboratory code referenced for Vita Risk (Arctic Medical Laboratories)
    81404Targeted genomic sequence analysis panel
    81408Exome or large panel molecular pathology (as listed)
    Inherited retinal dystrophies multigene panelsCPTCovered
    81434Deletion/duplication analysis, multiple exons or whole gene
    81406Sequencing test (previously referenced; removed for some tests per revision)
    Example ICD-10 codes for macular degenerationICD-10
    H35.30Macular degeneration, unspecified
    H35.3110Nonexudative age-related macular degeneration, right eye
    Example ICD-10 codes for inherited retinal dystrophiesICD-10
    H35.50Hereditary retinal dystrophy
    H35.54Other hereditary retinal dystrophy

    Provider Actions and Billing Guidance

    Prior Authorization

    Prior authorization: confirm clinical indication and panel content for inherited retinal dystrophy panels

    Order multigene panel testing for inherited retinal dystrophies only when the member has clinical findings consistent with rod-cone degeneration, cone-rod degeneration, chorioretinal degeneration, or macular dystrophy, and ensure the panel includes at minimum the RPE65 gene.

    • Clinical findings must match one of the listed phenotypes (rod‑cone, cone‑rod, chorioretinal, or macular dystrophy).
    • Panel must include the RPE65 gene as a minimum.
    Prior Authorization

    Verify code coverage and obtain prior authorization if applicable

    Verify current covered CPT codes before ordering and obtain prior authorization when required; note that some codes previously listed (for example CPT 81406 for a Fulgent Genetics macular degeneration test) were removed from the policy reference table and within criteria.

    • Check the updated policy reference table for acceptable/replacement test codes.

    Background

    Inherited and other genetic eye diseases are genetically heterogeneous: the policy notes that hundreds of genes are implicated in inherited retinal disorders and that the clinical presentation ranges from night or peripheral vision loss to progressive degenerative disease and blindness. By contrast, age-related macular degeneration (AMD) is described as a multifactorial condition for which routine genetic testing currently has limited clinical utility; testing is investigational unless a clear, guideline-supported genotype-directed intervention exists. For inherited retinal dystrophies, the policy requires specific clinical findings and inclusion of the RPE65 gene on multigene panels to meet medical necessity.

    Definitions

    Age-related Macular Degeneration (AMD)
    DefinitionAge-related Macular Degeneration (AMD) is the leading cause of blindness and irreversible vision loss among older adults (greater than age 65 years).
    Typical onsetPrimarily affects adults older than 65 years.
    Clinical impactCan cause progressive central vision loss potentially leading to legal blindness.
    Retinal dystrophies (RDs)
    DefinitionRetinal dystrophies (RDs) are degenerative diseases of the retina with marked clinical and genetic heterogeneity.
    Clinical spectrumVision impairment ranges from poor peripheral or night vision to complete blindness.
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyConcert Genetic Testing: Eye Disorders V1.2025
    Policy CodePolicy N/A
    Change TypeCriteria updates and code removals (material)
    Effective DateN/A
    Last ReviewNov 24, 2024
    Next Review DateN/A
    Key ActionVerify current covered test codes and obtain prior authorization when required before ordering genetic tests for inherited retinal dystrophies.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Test ReferencesProvider Actions and Billing GuidanceBackgroundDefinitions
    Retinitis Pigmentosa was removed from the 'Other Covered Eye Disorders' list because it is addressed under the Inherited Retinal Dystrophies Multigene Panel Analysis criteria.
  1. Obtain prior authorization for the replacement/updated test if required by the plan.
  2. Step Therapy

    Testing stewardship: order the most specific test(s) for the clinical presentation

    Avoid unnecessary parallel or broad testing; order the most specific genetic test(s) appropriate to the patient's clinical findings and reserve massively parallel strategies (WES/WGS) for research or tertiary care settings when appropriate.

    • Prefer targeted panels tailored to the suspected phenotype over routine broad exome/genome testing.
    • Restrict whole‑exome or whole‑genome sequencing to research studies or tertiary care where indicated.
    Step Therapy

    No step therapy requirements specified

    There are no explicit step therapy requirements described in this policy excerpt.

    Documentation Required

    Document pathogenic RPE65 variants and confirm trans configuration when two variants are found

    When RPE65 testing identifies pathogenic or likely pathogenic variants, document that variants are present in both copies (biallelic) and—if two variants are detected—provide additional documentation confirming they are in trans configuration to establish RPE65‑mediated disease.

    • Report pathogenic or likely pathogenic variants present in both alleles to establish a biallelic diagnosis.
    • If two variants are detected by sequencing, include evidence (e.g., familial testing or phase determination) that they are in trans.
    Documentation Required

    Use CLIA‑certified labs, share reports with patients, and involve inherited disease experts

    Use CLIA‑certified laboratories for clinical genetic testing, provide a written copy of the genetic test report to the patient, and involve a physician with inherited disease expertise or a genetic counselor for interpretation and counseling.

    • Ensure testing is performed in a CLIA‑approved laboratory.
    • Provide the patient with a copy of the genetic test report.
    • Engage a physician experienced in inherited disease or a certified genetic counselor for pre‑ and post‑test counseling.
    Documentation Required

    Provide guideline‑based clinical documentation to support testing

    Support genetic testing decisions and prior authorization with clinical documentation referencing current guideline‑based criteria (for example AAO and ASRS guidance) and the updated test panel composition listed in the policy.

    • Include citation(s) to relevant guideline recommendations and the clinical findings that meet policy criteria.
    • Document the specific genes/panel composition ordered and how it aligns with policy requirements.
    Denial Risk

    Denial risk: genetic testing for macular degeneration is investigational

    Do not expect coverage for genetic testing for macular degeneration; testing for AMD using listed CPTs (81404, 81408, 81479, 81599, 0205U) is considered investigational and claims may be denied for these indications.

    • Avoid ordering these tests for macular degeneration unless part of an approved research protocol or other covered indication.
    Denial Risk

    Retired or removed tests/codes may lead to claim denials

    Tests or criteria sets retired or removed from the policy reference table (for example CPT 81406 removed from a listed Fulgent Genetics macular degeneration test) may no longer be covered; submitting claims using retired/removed codes or for retired tests may trigger denials or require updated coding and authorization.

    • Confirm the test and CPT code are still listed as covered in the current policy before submission.
    • If a code was removed, identify the updated/replacement test and obtain prior authorization as needed.
    Natural history
    Severity usually increases with age.
    RPE65 gene
    Gene productRPE65 encodes an RPE-specific 65-kD protein that functions as a retinal isomerase in the visual cycle.
    Biologic roleResponsible for regeneration of 11-cis-retinol in the retinal pigment epithelium (RPE).
    Clinical relevancePathogenic biallelic variants cause an inherited retinal dystrophy that can be amenable to gene-directed therapies.
    Gene therapy
    DefinitionGene therapy is a treatment that changes the expression of genes to treat disease, e.g., by replacing or inactivating a malfunctioning gene or introducing a new gene.
    DeliveryGenes may be introduced into human cells through a vector, usually a virus.
    Therapeutic goalUsed to modify gene expression to prevent or treat inherited retinal disorders when appropriate.
    Inherited Retinal Dystrophies Multigene Panel Analysis (updated criteria set name)
    Updated nameInherited Retinal Dystrophies Multigene Panel Analysis (criteria set renamed from 'RPE65 Sequencing and/or Deletion/Duplication Analysis').
    Scope changeClinical criteria were updated to be more consistent with guideline recommendations.
    Related editsPolicy removed Retinitis Pigmentosa from 'Other Covered Eye Disorders' because it is now covered under this renamed criteria set.
    VersioningTitle updated to reflect V1.2025; access/reference dates for online resources were updated.